According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.26309. At the end of 2023 the company had a P/S ratio of 2.92.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.92 | -51.95% |
2022 | 6.08 | 56.69% |
2021 | 3.88 | 31.08% |
2020 | 2.96 | -73.21% |
2019 | 11.1 | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.69 | -36.99% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | 8.09 | 89.84% | ๐บ๐ธ USA |
Ultragenyx RARE | 8.85 | 107.66% | ๐บ๐ธ USA |
Lexicon Pharmaceuticals
LXRX | > 1000 | 26,006.42% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | 8.71 | 104.38% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 6.91 | 62.14% | ๐บ๐ธ USA |